Articles

Zimmer looks to China to reignite growth

Zimmer Holdings Inc. completed an acquisition in China on Tuesday, but recession hangovers in the United States and Europe are trumping all other factors and keeping the company’s growth bottled up for now.

Read More

Lilly scores series of small victories

The Indianapolis-based drugmaker finally won FDA approval for its antidepressant Cymbalta to treat chronic pain and fended off a patent challenge to rising-star cancer drug Alimta, but got a ratings downgrade on its debt.

Read More

Lilly makes $300M deal for Philadelphia drug company

Eli Lilly said it will acquire Avid Radiopharmaceuticals, maker of an experimental agent that could help identify patients with Alzheimer’s disease. The price could climb to $800 million if the agent is commercially successful.

Read More

Seeking growth, Lilly dumps Singapore for China

After recently deciding to close a research center in Singapore, Indianapolis-based Eli Lilly and Co. has decided to open a diabetes research center in China in the second half of 2011, further ramping up the drugmaker’s presence in the world’s fastest-growing pharmaceutical market.

Read More

Eli Lilly will have to beat odds to meet drug-rollout goals

Eli Lilly and Co. executives have said repeatedly that the company’s bulging pipeline will produce two new drugs per year, beginning in 2013. But only three times in the past six decades has Lilly been able to launch two or more new drugs in back-to-back years.

Read More